386 related articles for article (PubMed ID: 30690682)
1. Cost-Effectiveness Analysis of Cytoreductive Surgery and HIPEC Compared With Systemic Chemotherapy in Isolated Peritoneal Carcinomatosis From Metastatic Colorectal Cancer.
Hamilton TD; MacNeill AJ; Lim H; Hunink MGM
Ann Surg Oncol; 2019 Apr; 26(4):1110-1117. PubMed ID: 30690682
[TBL] [Abstract][Full Text] [Related]
2. Cost Effectiveness of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Management of Colorectal Peritoneal Carcinomatosis.
Lee ZJ; Chia SL; Tan G; Soo KC; Teo CCM
Ann Surg Oncol; 2018 Aug; 25(8):2340-2346. PubMed ID: 29948417
[TBL] [Abstract][Full Text] [Related]
3. Quality of life and cost effectiveness in a randomized trial of patients with colorectal cancer and peritoneal metastases.
Cashin PH; Mahteme H; Syk I; Frödin JE; Glimelius B; Graf W
Eur J Surg Oncol; 2018 Jul; 44(7):983-990. PubMed ID: 29530346
[TBL] [Abstract][Full Text] [Related]
4. Predictors of progression in high-grade appendiceal or colorectal peritoneal carcinomatosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Baumgartner JM; Tobin L; Heavey SF; Kelly KJ; Roeland EJ; Lowy AM
Ann Surg Oncol; 2015 May; 22(5):1716-21. PubMed ID: 25145504
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in a community setting: A cost-utility analysis of a hospital's initial experience and reflections on the health care system.
Naffouje SA; O'Donoghue C; Salti GI
J Surg Oncol; 2016 Apr; 113(5):544-7. PubMed ID: 26750613
[TBL] [Abstract][Full Text] [Related]
6. Treatment of intraoperatively detected peritoneal carcinomatosis of colorectal origin with cytoreductive surgery and intraperitoneal chemotherapy.
Canda AE; Arslan C; Terzi C; Sokmen S; Yavuzsen T; Ozkardesler S; Unlu M; Obuz F; Fuzun M
World J Surg Oncol; 2018 Mar; 16(1):70. PubMed ID: 29587771
[TBL] [Abstract][Full Text] [Related]
7. Peritoneal carcinomatosis index predicts survival in colorectal patients undergoing HIPEC using oxaliplatin: a retrospective single-arm cohort study.
Burnett A; Lecompte MA; Trabulsi N; Dubé P; Gervais MK; Trilling B; Cloutier AS; Sideris L
World J Surg Oncol; 2019 May; 17(1):83. PubMed ID: 31092250
[TBL] [Abstract][Full Text] [Related]
8. Indications for hyperthermic intraperitoneal chemotherapy with cytoreductive surgery: a systematic review.
Auer RC; Sivajohanathan D; Biagi J; Conner J; Kennedy E; May T
Eur J Cancer; 2020 Mar; 127():76-95. PubMed ID: 31986452
[TBL] [Abstract][Full Text] [Related]
9. Hepatectomy for metachronous colorectal liver metastases following complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases: a report of three cases.
Ito K; Takemura N; Inagaki F; Mihara F; Kurokawa T; Gohda Y; Kiyomatsu T; Yano H; Kokudo N
World J Surg Oncol; 2019 Jun; 17(1):99. PubMed ID: 31196097
[TBL] [Abstract][Full Text] [Related]
10. Perioperative Systemic Chemotherapy, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy in Patients With Colorectal Peritoneal Metastasis: Results of the Prospective Multicenter Phase 2 COMBATAC Trial.
Glockzin G; Zeman F; Croner RS; Königsrainer A; Pelz J; Ströhlein MA; Rau B; Arnold D; Koller M; Schlitt HJ; Piso P
Clin Colorectal Cancer; 2018 Dec; 17(4):285-296. PubMed ID: 30131226
[TBL] [Abstract][Full Text] [Related]
11. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ
Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139
[TBL] [Abstract][Full Text] [Related]
12. Sites of Recurrence After Complete Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Colorectal and Appendiceal Adenocarcinoma: A Tertiary Center Experience.
Feferman Y; Solomon D; Bhagwandin S; Kim J; Aycart SN; Feingold D; Sarpel U; Labow DM
Ann Surg Oncol; 2019 Feb; 26(2):482-489. PubMed ID: 30539491
[TBL] [Abstract][Full Text] [Related]
13. Effect of hyperthermic intraperitoneal chemotherapy in combination with cytoreductive surgery on the prognosis of patients with colorectal cancer peritoneal metastasis: a systematic review and meta-analysis.
Li J; Wang AR; Chen XD; Zhang YX; Pan H; Li SQ
World J Surg Oncol; 2022 Jun; 20(1):200. PubMed ID: 35701802
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy with bevacizumab may improve outcome after cytoreduction and hyperthermic intraperitoneal chemoperfusion (HIPEC) for colorectal carcinomatosis.
Ceelen W; Van Nieuwenhove Y; Putte DV; Pattyn P
Ann Surg Oncol; 2014 Sep; 21(9):3023-8. PubMed ID: 24756812
[TBL] [Abstract][Full Text] [Related]
15. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial.
Koole SN; van Lieshout C; van Driel WJ; van Schagen E; Sikorska K; Kieffer JM; Schagen van Leeuwen JH; Schreuder HWR; Hermans RH; de Hingh IH; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AG; Verwaal VJ; Van de Vijver KK; Aaronson NK; van Tinteren H; Sonke GS; van Harten WH; Retèl VP
J Clin Oncol; 2019 Aug; 37(23):2041-2050. PubMed ID: 31251694
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the cost-effectiveness of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (peritonectomy) at the St George Hospital peritoneal surface malignancy program.
Chua TC; Martin S; Saxena A; Liauw W; Yan TD; Zhao J; Lok I; Morris DL
Ann Surg; 2010 Feb; 251(2):323-9. PubMed ID: 20040853
[TBL] [Abstract][Full Text] [Related]
17. Escalation of socioeconomic disparities among patients with colorectal cancer receiving advanced surgical treatment.
Tabrizian P; Overbey J; Carrasco-Avino G; Bagiella E; Labow DM; Sarpel U
Ann Surg Oncol; 2015 May; 22(5):1746-50. PubMed ID: 25388060
[TBL] [Abstract][Full Text] [Related]
18. Association between hospital finances, payer mix, and complications after hyperthermic intraperitoneal chemotherapy: deficiencies in the current healthcare reimbursement system and future implications.
Squires MH; Staley CA; Knechtle W; Winer JH; Russell MC; Perez S; Sweeney JF; Maithel SK; Staley CA
Ann Surg Oncol; 2015 May; 22(5):1739-45. PubMed ID: 25249258
[TBL] [Abstract][Full Text] [Related]
19. More Synchronous Peritoneal Disease but Longer Survival in Younger Patients with Carcinomatosis from Colorectal Cancer Undergoing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy.
Solomon D; DeNicola NL; Feferman Y; Bekhor E; Reppucci ML; Feingold D; Aycart SN; Magge DR; Golas BJ; Labow DM; Sarpel U
Ann Surg Oncol; 2019 Mar; 26(3):845-851. PubMed ID: 30643994
[TBL] [Abstract][Full Text] [Related]
20. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy versus palliative systemic chemotherapy in stomach cancer patients with peritoneal dissemination, the study protocol of a multicentre randomised controlled trial (PERISCOPE II).
Koemans WJ; van der Kaaij RT; Boot H; Buffart T; Veenhof AAFA; Hartemink KJ; Grootscholten C; Snaebjornsson P; Retel VP; van Tinteren H; Vanhoutvin S; van der Noort V; Houwink A; Hahn C; Huitema ADR; Lahaye M; Los M; van den Barselaar P; Imhof O; Aalbers A; van Dam GM; van Etten B; Wijnhoven BPL; Luyer MDP; Boerma D; van Sandick JW
BMC Cancer; 2019 May; 19(1):420. PubMed ID: 31060544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]